COMP <GO>
INVA vs ABBV // FREE CASH FLOW YIELD
Innoviva Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: INVA 5
— ABBV 5
▲ FREE CASH FLOW YIELD LEADER: INVA
LAST: $21.31 (+0.90%) • MKT CAP: $1.54B
fcf-yield
12.72%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INVA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INVA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.80% | 70.20% | +4.60 | INVA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.70% | 29.00% | -14.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.6x | 33.3x | -25.70 | INVA | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 12.72% | 3.47% | +9.25 | INVA | /fcf-yield <GO> |
| Operating Margin | 39.80% | 24.60% | +15.20 | INVA | /operating-margins <GO> |
| Net Profit Margin | — | 6.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 14.70% | 8.60% | +6.10 | INVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.4 | 65.1 | -11.70 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.54B | $513.86B | -$512.32B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INVA REV | ABBV REV | INVA GROSS % | ABBV GROSS % | INVA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $411.3M | $61.16B | 74.8% | 70.2% | $195.8M | $17.82B |
| FY 2024 | $358.7M | $56.33B | 82.6% | 70.0% | $188.4M | $17.83B |
| FY 2023 | $310.5M | $54.32B | — | — | $141.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INVA // BETA —
ABBV // BETA 1.15